IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 5397 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (60 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed1938    
    Printed123    
    Emailed0    
    PDF Downloaded112    
    Comments [Add]    

Recommend this journal

 


 
CORRESPONDENCE
Year : 2006  |  Volume : 38  |  Issue : 6  |  Page : 438
 

Reply


Department of Biochemistry, Amrita Institute of Medical Sciences, Elamakkara P.O., Cochin-682 026, India

Correspondence Address:
S K Das
Department of Biochemistry, Amrita Institute of Medical Sciences, Elamakkara P.O., Cochin-682 026
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions



How to cite this article:
Das S K, Vasudevan D M. Reply. Indian J Pharmacol 2006;38:438

How to cite this URL:
Das S K, Vasudevan D M. Reply. Indian J Pharmacol [serial online] 2006 [cited 2020 Feb 28];38:438. Available from: http://www.ijp-online.com/text.asp?2006/38/6/438/28218


We sincerely appreciate the interest shown by the readers in our article entitled "Drugs and non-alcoholic steatohepatitis" (Indian J Pharmacol 2006;38:238-42). Non-alcoholic steatohepatitis (NASH) has been associated with obesity, diabetes, hypertriglyceridemia and hypertension. In addition, NASH has also been associated with hyperlipoproteinemia, jejunal bypass surgery, parenteral nutrition and drugs. In this article, we highlighted lists of drugs that are commonly used for the treatment of obesity, diabetes, hypertriglyceridemia and hypertension, irrespective of geographical barrier, and associated with hepatoxicity. We also tried to discuss briefly the mechanism of action of these drugs. A number of pharmacologic agents have been shown to be promising in the treatment of NASH, but they need to be studied further. In fact, a trial, utilizing troglitazone, had shown encouraging results, but because of reports of rare but serious hepatotoxicity, the drug has now been withdrawn from the market.[1] Therefore, awareness about these hazardous drugs is very important.

 
  References Top

1.Das SK, Mukherjee S, Vasudevan DM. Non-alcoholic fatty liver disease: An underrecognized cause with emerging importance. Curr Sci 2006;90:659-65.  Back to cited text no. 1    




 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow